1. Home
  2. XLO

as of 12-15-2025 3:56pm EST

$0.65
$0.02
-3.37%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Chart Type:
Time Range:
Founded: 2016 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 41.8M IPO Year: 2021
Target Price: $2.00 AVG Volume (30 days): 528.0K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.13 EPS Growth: N/A
52 Week Low/High: $0.61 - $1.70 Next Earning Date: 11-13-2025
Revenue: $31,804,000 Revenue Growth: 588.40%
Revenue Growth (this year): 589.6% Revenue Growth (next year): 38.00%

AI-Powered XLO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 73.15%
73.15%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: